Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed the BSE about the submission of an intimation of AGM date, scheduling the 32nd Annual General Meeting on September 30, 2026. The register of members and share transfer books will be closed from September 24 to September 30, 2026, for the purpose of the AGM. The remote e-voting period will begin on September 27 and end on September 29, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed the BSE about the appointment of Mr. Gnana Prakash Gattu as Whole-time Director of the company for a period of five years, effective from August 29, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced the outcome of its board meeting, which was held on August 29, 2026. The board has approved the appointment of Gnana Prakash Gattu as a whole-time director of the company, effective from August 29, 2026. The company has also announced the date of its annual general meeting, which will be held on September 30, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 29/08/2026 to consider and approve Submission of Prior Intimation Of Board Meeting, including the 32nd Annual General Meeting, Board Report, appointment of Scrutinizer, and Whole Time Director.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has executed a 5-year land lease deed with Mr. Gnana Prakash Gattu for Micro Algae Cultivation and Glass Reactor Systems at Telangana, India.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has submitted its unaudited financial results for the quarter ended 30th June, 2026, showing a net profit of Rs. 352.48 crore and earnings per share of Rs. 2.32.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd submitted a statement of deviation and variation as per SEBI (Listing Obligation and Disclosure Requirements) 2015 for the quarter ended 30th June, 2026. The company has raised funds to meet long-term funding requirements, including working capital and general corporate purposes, to support its future growth plan.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced its unaudited standalone financial results for the quarter ended 30th June, 2026, with revenue from operations at Rs. 3,691.39 lakhs and total expenses at Rs. 3,579.98 lakhs, resulting in a profit from ordinary activities before exceptional items of Rs. 111.53 lakhs.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with revenue from operations at Rs. 3,691.39 lakhs and total expenses at Rs. 3,579.98 lakhs.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 13/08/2026 to consider and approve the unaudited standalone financial results for the quarter ended on June 30, 2026.

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has confirmed that it does not qualify as a 'Large Corporate' (LC) entity under the SEBI framework for the financial year 2025-2026. This disclosure was made in response to a BSE query, with the company reporting zero outstanding borrowings as of March 31, 2025. This classification means the company is not subject to the additional compliance obligations applicable to Large Corporates.